Biotech Sector Faces Challenges as Vera Therapeutics Hits Yearly Low Vera Therapeutics' stock has dropped to $25.97, nearing its 52-week low amidst a challenging year for biotech firms. The company's financials remain strong, with $640.9 million in cash, but market concerns persist. Investors await Phase 3 trial results for atacicept, a potential game-changer in the IgAN treatment landscape.12